The last decade has seen an explosion in clinical research focusing on the use of
noninvasive biomarkers in kidney transplantation. Much of the published literature focuses …

Currently in the United States, there are more than 250,000 patients with a functioning
kidney allograft and over 100,000 waitlisted patients awaiting kidney transplant, with a …

Simple Summary Patients who have undergone solid-organ transplant are at higher risk of
developing aggressive cutaneous squamous cell carcinoma (CSCC), which is associated …

Background Donor-derived cell-free DNA (dd-cfDNA) is a promising non-invasive biomarker
for detecting graft injury in solid organ transplant recipients. Elevated dd-cfDNA levels are …

Alloimmune injury is a major cause of long-term kidney allograft failure whether due to
functionally stable (subclinical) or overt clinical rejection. These episodes may be mediated …

Background. Presensitized patients with circulating donor-specific antibodies (DSAs) before
transplantation are at risk for antibody-mediated rejection (AMR). Peritransplant …

Background Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance
for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR) …

Background. Immunosuppression therapy (IST) is required for allograft survival but can
cause significant adverse effects. Donor-derived cell-free DNA (dd-cfDNA) is a validated …

Traditional monitoring of kidney transplant recipients for allograft dysfunction caused by
rejection involves serial checks of serum creatinine with biopsy of the renal allograft if …

Acute rejection is a major impediment to long-term allograft function, 1 which is a critically
important outcome for kidney transplant recipients, caregivers, and health professionals. 2 …